ActoGeniX Report issue

For profit Phase 1 Phase 2
Founded: Ghent Belgium (2006)
Status: Acquired by Intrexon (2015)

Organization Overview

First Clinical Trial
2008
NCT00729872
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2009

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

ActoGeniX N.V. | Chief Medical Officer ActoGeniX NV | Project Manager ActoGeniX NV

Active Ingredients

Drugs in Phase 2 Trials (1)

ag011 (1 trial)

Drugs in Phase 1 Trials (1)

ag013 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Colitis (Phase 2)

Colitis, Ulcerative (Phase 2)

Head and Neck Neoplasms (Phase 1)

Mucositis (Phase 1)

Stomatitis (Phase 1)

Ulcer (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2